1
|
Yin H, Ye R, Yang Y, Wang J, Tang R, Yao S, Duan S, Ding Y, He N. Longitudinal impact of compliance with routine CD4 monitoring on all cause deaths among treated people with HIV in China. Biosci Trends 2022; 16:434-443. [PMID: 36504071 DOI: 10.5582/bst.2022.01479] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/14/2022]
Abstract
Keeping adherence to the continuous and standardized CD4 follow-up monitoring service is of great significance to the control of disease progression and the reduction of avoidable mortality for HIV-infected patients. As non-communicable diseases (NCDs) have become main causes of deaths for people with HIV (PWH) in the era of combination antiretroviral therapy (cART), how and to what extent does adherence to routine CD4 monitoring differentially impact on AIDS-related versus NCDs-related deaths in low- and middle-income countries (LMIC) remains elucidated. A CD4 test index was developed by dividing the actual number of received CD4 tests by the theoretical number of CD4 tests that should have been performed according to national treatment guidelines during the study period, with an index value of 0.8-1.2 reflecting compliance. From 1989 to 2020, 14,571 adults were diagnosed with HIV infection in Dehong Prefecture of Yunnan province in Southwestern China, 6,683 (45.9%) PWH had died with the all-cause mortality of 550.13 per 10,000 person-years, including 3,250 (48.6%) AIDS-related deaths (267.53 per 10,000 person-years). Among patients on cART, the median CD4 test index was 1.0 (IQR 0.6-1.3), and 35.2% had a CD4 test index less than 0.8. Cox proportional hazards regression analysis indicated that PWH with CD4 test index at 0.8-1.2 were at the lowest risk of both AIDS-related (aHR = 0.06; 95%CI: 0.05-0.07) and NCDs-related (aHR = 0.13; 95%CI: 0.11-0.16)deaths. Adherence to routine CD4 monitoring is critical for reducing both AIDS-related and NCDs-related mortality of PWH. An appropriate (once or twice a year) rather than an unnecessarily higher frequency of routine CD4 testing could be most cost-effective in reducing mortality in LMIC.
Collapse
Affiliation(s)
- Hao Yin
- Department of Epidemiology, School of Public Health, and Shanghai Institute of Infectious Diseases and Biosecurity, Fudan University, Shanghai, China.,Key Laboratory of Public Health Safety of Ministry of Education, Fudan University, Shanghai, China.,Yi-Wu Research Institute, Fudan University, Shanghai, China
| | - Runhua Ye
- Dehong Prefecture Center for Disease Control and Prevention, Dehong, Yunnan, China
| | - Yuecheng Yang
- Dehong Prefecture Center for Disease Control and Prevention, Dehong, Yunnan, China
| | - Jibao Wang
- Dehong Prefecture Center for Disease Control and Prevention, Dehong, Yunnan, China
| | - Renhai Tang
- Dehong Prefecture Center for Disease Control and Prevention, Dehong, Yunnan, China
| | - Shitang Yao
- Dehong Prefecture Center for Disease Control and Prevention, Dehong, Yunnan, China
| | - Song Duan
- Dehong Prefecture Center for Disease Control and Prevention, Dehong, Yunnan, China
| | - Yingying Ding
- Department of Epidemiology, School of Public Health, and Shanghai Institute of Infectious Diseases and Biosecurity, Fudan University, Shanghai, China.,Yi-Wu Research Institute, Fudan University, Shanghai, China
| | - Na He
- Department of Epidemiology, School of Public Health, and Shanghai Institute of Infectious Diseases and Biosecurity, Fudan University, Shanghai, China.,Key Laboratory of Public Health Safety of Ministry of Education, Fudan University, Shanghai, China.,Yi-Wu Research Institute, Fudan University, Shanghai, China
| |
Collapse
|
2
|
Brief Report: Drop in CD4+ Counts Below 200 Cells/μL After Reaching (or Starting From) Values Higher than 350 Cells/μL in HIV-Infected Patients With Virological Suppression. J Acquir Immune Defic Syndr 2018; 76:417-422. [PMID: 28816721 DOI: 10.1097/qai.0000000000001522] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/25/2022]
Abstract
BACKGROUND The aim of the study was to quantify the risk of a drop in CD4 counts below 200 cells/μL after reaching values >350 cells/μL on antiretroviral therapy (ART) (or after starting ART with CD4 count >350 cells/μL) in the absence of virological failure. SETTING Ambulatory care services, Italy. METHODS Prospective cohort study of patients enrolled in the ICONA Foundation Study cohort who started ART with >350 CD4/μL or with ≤350 CD4/μL and reached values >350 cells/μL after virological suppression (VS, defined by 2 consecutive viral loads ≤50 copies/mL). The date of CD4 count >350 was the baseline for the analysis and those with ≥1 viral load and CD4 count after baseline were included. The primary end point was the cumulative risk (estimated using the Kaplan-Meier method) of a CD4 drop below 200 cells/μL over follow-up, which was censored at the date of virological failure (confirmed HIV-RNA >50 copies/mL), death, or last visit. RESULTS Six thousand six hundred sixty-three patients were included. A confirmed CD4 drop below 200 cells/μL was never observed over a median follow-up of 45 (Q1: 21, Q3: 89) months, as long as VS was maintained. Upper limits of the 97.5% confidence interval of rates of confirmed CD4 drop below 200 cells/μL were 0.28 and 0.38/1000 person-years of follow-up for patients with ≤350 and >350 CD4 cells/μL at starting ART. CONCLUSIONS In patients who started ART in Italy with >350 CD4 cells/μL or reached >350 CD4 cells/μL after VS, the risk of a CD4 drop below 200 cells/μL in those maintaining VS was negligible.
Collapse
|